Oxygen Biotherapeutics Inc announced it has signed a Definitive Agreement (Agreement) to acquire certain assets of Phyxius Pharma, a privately-held biopharmaceutical company focused on the development and near-term commercialization of levosimendan to prevent and treat cardiac surgery patients at risk for developing low cardiac output syndrome (LCOS), an unmet medical need addressing an estimated $600 million market in the U.S. According to the terms of the Agreement,
going to the moon good luck
I have been watching this for a month now and seen the news released yesterday in the AH market and seen the price spike. Should I wait until the end of the day to invest or should buy now. I hate chasing stocks thats why im asking.